|
2024-02-15 |
2024-02-15 |
B
Compra
|
See Remarks
Consejero ejecutivo
|
86 180
-41.7%
24,25
4.896.087 US$
|
86 180
-41.7%
|
24,25
|
4.896.087 US$
|
|
|
2023-11-17 |
2023-11-15 |
B
Compra
|
Consejero no ejecutivo
|
66 742
-0.8%
229,71
4.589.587 US$
|
66 742
-0.8%
|
229,71
|
4.589.587 US$
|
|
|
2022-01-06 |
2022-01-06 |
S
Venta
|
Chief Medical Officer
Oficial
|
88 536
+42.0%
439,37
1.813.479 US$
|
88 536
+42.0%
|
439,37
|
1.813.479 US$
|
|
|
2021-09-14 |
2021-09-13 |
S
Venta
|
Chairman and CEO
Consejero ejecutivo
|
82 107
-9.6%
6,50
533.696 US$
|
82 107
-9.6%
|
6,50
|
533.696 US$
|
|
|
2021-09-14 |
2021-09-10 |
S
Venta
|
PFO & PAO
Oficial
|
11 120
-10.7%
6,50
72.280 US$
|
11 120
-10.7%
|
6,50
|
72.280 US$
|
|
|
2020-06-18 |
2020-06-17 |
S
Venta
|
Gran accionista
|
141 920
-0.8%
3,66
518.831 US$
|
141 920
-0.8%
|
3,66
|
518.831 US$
|
|
|
2020-06-18 |
2020-06-16 |
S
Venta
|
Gran accionista
|
72 080
-0.4%
3,66
264.007 US$
|
72 080
-0.4%
|
3,66
|
264.007 US$
|
|
|
2020-06-15 |
2020-06-15 |
S
Venta
|
Gran accionista
|
384 025
-2.2%
3,57
1.372.160 US$
|
384 025
-2.2%
|
3,57
|
1.372.160 US$
|
|
|
2020-06-15 |
2020-06-12 |
S
Venta
|
Gran accionista
|
9 100
-0.1%
3,58
32.556 US$
|
9 100
-0.1%
|
3,58
|
32.556 US$
|
|
|
2020-06-15 |
2020-06-11 |
S
Venta
|
Gran accionista
|
183 875
-1.0%
3,77
692.786 US$
|
183 875
-1.0%
|
3,77
|
692.786 US$
|
|
|
2017-12-14 |
2017-12-12 |
S
Venta
|
Baysal Ozer
Chief Commercial Officer
|
3 712
-5.9%
3,46
12.846 US$
|
3 712
-5.9%
|
3,46
|
12.846 US$
|
|
|
2017-12-14 |
2017-12-12 |
S
Venta
|
Valentine Karen
Chief Legal Officer
|
8 358
-7.6%
3,46
28.921 US$
|
8 358
-7.6%
|
3,46
|
28.921 US$
|
|
|
2017-12-14 |
2017-12-12 |
S
Venta
|
Duncan Alex
Chief Technology Officer
|
6 546
-23.7%
3,46
22.651 US$
|
6 546
-23.7%
|
3,46
|
22.651 US$
|
|
|
2017-12-14 |
2017-12-12 |
S
Venta
|
Buell Jennifer
Chief Communications Officer
|
3 511
-9.0%
3,46
12.152 US$
|
3 511
-9.0%
|
3,46
|
12.152 US$
|
|
|
2017-12-14 |
2017-12-12 |
S
Venta
|
KLASKIN CHRISTINE M
VP, Finance
|
5 610
-8.0%
3,46
19.418 US$
|
5 610
-8.0%
|
3,46
|
19.418 US$
|
|
|
2017-04-12 |
2017-04-12 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Consejero ejecutivo
|
29 456
+2.1%
3,29
97.055 US$
|
29 456
+2.1%
|
3,29
|
97.055 US$
|
|
|
2017-04-12 |
2017-04-10 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Consejero ejecutivo
|
70 544
+5.4%
3,37
237.465 US$
|
70 544
+5.4%
|
3,37
|
237.465 US$
|
|
|
2017-02-14 |
2017-02-14 |
B
Compra
|
INCYTE CORP
Gran accionista
|
10 000 000
+128.8%
6,00
60.000.000 US$
|
10 000 000
+128.8%
|
6,00
|
60.000.000 US$
|
|
|
2016-09-08 |
2016-09-06 |
B
Compra
|
WIINBERG ULF
Consejero no ejecutivo
|
30 000
+inf%
6,29
188.700 US$
|
30 000
+inf%
|
6,29
|
188.700 US$
|
|
|
2016-05-10 |
2016-05-09 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
50 000
+3.7%
3,28
163.935 US$
|
50 000
+3.7%
|
3,28
|
163.935 US$
|
|
|
2016-05-10 |
2016-05-05 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
50 000
+3.9%
3,08
153.960 US$
|
50 000
+3.9%
|
3,08
|
153.960 US$
|
|
|
2016-05-09 |
2016-05-05 |
B
Compra
|
Baysal Ozer
Chief Business Officer
Oficial
|
2 250
+7.2%
3,10
6.975 US$
|
2 250
+7.2%
|
3,10
|
6.975 US$
|
|
|
2016-03-08 |
2016-03-07 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
200 000
+19.0%
4,03
805.600 US$
|
200 000
+19.0%
|
4,03
|
805.600 US$
|
|
|
2015-12-30 |
2015-12-29 |
S
Venta
|
ARMEN GARO H
Chairman & CEO
Oficial
|
85 224
-6.6%
4,57
389.602 US$
|
85 224
-6.6%
|
4,57
|
389.602 US$
|
|
|
2015-12-30 |
2015-12-28 |
S
Venta
|
ARMEN GARO H
Chairman & CEO
Oficial
|
89 917
-6.5%
4,59
413.142 US$
|
89 917
-6.5%
|
4,59
|
413.142 US$
|
|
|
2015-12-30 |
2015-12-28 |
S
Venta
|
ARMEN GARO H
Chairman & CEO
Oficial
|
44 435
-3.1%
4,62
205.134 US$
|
44 435
-3.1%
|
4,62
|
205.134 US$
|
|
|
2015-09-29 |
2015-09-25 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
100 000
+7.6%
5,03
503.000 US$
|
100 000
+7.6%
|
5,03
|
503.000 US$
|
|
|
2015-09-29 |
2015-09-25 |
B
Compra
|
Ballantyne Charles Evan
Chief Financial Officer
Oficial
|
10 000
+inf%
5,05
50.500 US$
|
10 000
+inf%
|
5,05
|
50.500 US$
|
|
|
2015-04-30 |
2015-04-29 |
S
Venta
|
Malik Shahzad
Consejero no ejecutivo
|
407 377
-100.0%
7,02
2.858.809 US$
|
407 377
-100.0%
|
7,02
|
2.858.809 US$
|
|
|
2015-04-30 |
2015-04-28 |
S
Venta
|
Malik Shahzad
Consejero no ejecutivo
|
700 000
-63.2%
7,16
5.012.560 US$
|
700 000
-63.2%
|
7,16
|
5.012.560 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
41 830
-0.6%
5,33
222.954 US$
|
41 830
-0.6%
|
5,33
|
222.954 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
83 100
-1.2%
5,31
441.261 US$
|
83 100
-1.2%
|
5,31
|
441.261 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
100 000
-1.4%
5,35
535.000 US$
|
100 000
-1.4%
|
5,35
|
535.000 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
89 800
-1.2%
5,49
493.002 US$
|
89 800
-1.2%
|
5,49
|
493.002 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
50 000
-0.7%
5,44
272.000 US$
|
50 000
-0.7%
|
5,44
|
272.000 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
100 000
-1.4%
5,20
520.000 US$
|
100 000
-1.4%
|
5,20
|
520.000 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
43 080
-0.6%
5,57
239.956 US$
|
43 080
-0.6%
|
5,57
|
239.956 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
856 920
-10.3%
5,18
4.438.846 US$
|
856 920
-10.3%
|
5,18
|
4.438.846 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
215 000
-2.5%
5,19
1.115.850 US$
|
215 000
-2.5%
|
5,19
|
1.115.850 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
400 000
-4.5%
5,62
2.248.000 US$
|
400 000
-4.5%
|
5,62
|
2.248.000 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
53 606
-0.6%
5,21
279.287 US$
|
53 606
-0.6%
|
5,21
|
279.287 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
146 394
-1.6%
5,27
771.496 US$
|
146 394
-1.6%
|
5,27
|
771.496 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
143 900
-1.6%
5,30
762.670 US$
|
143 900
-1.6%
|
5,30
|
762.670 US$
|
|
|
2015-01-13 |
2015-01-09 |
S
Venta
|
QVT Associates GP LLC
Gran accionista
|
20 000
-0.2%
5,55
111.000 US$
|
20 000
-0.2%
|
5,55
|
111.000 US$
|
|
|
2011-12-29 |
2011-12-29 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
8 939
-36.6%
2,01
17.967 US$
|
8 939
-36.6%
|
2,01
|
17.967 US$
|
|
|
2011-12-29 |
2011-12-29 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
7 605
-86.5%
1,98
15.058 US$
|
7 605
-86.5%
|
1,98
|
15.058 US$
|
|
|
2011-12-29 |
2011-12-28 |
S
Venta
|
Sharp Shalini
CFO
Oficial
|
1 711
-3.9%
2,09
3.576 US$
|
1 711
-3.9%
|
2,09
|
3.576 US$
|
|
|
2011-12-29 |
2011-12-28 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
1 893
-7.2%
2,09
3.956 US$
|
1 893
-7.2%
|
2,09
|
3.956 US$
|
|
|
2011-12-29 |
2011-12-28 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
1 301
-12.9%
2,09
2.719 US$
|
1 301
-12.9%
|
2,09
|
2.719 US$
|
|
|
2011-12-29 |
2011-12-27 |
S
Venta
|
Sharp Shalini
CFO
Oficial
|
2 853
-6.2%
2,14
6.105 US$
|
2 853
-6.2%
|
2,14
|
6.105 US$
|
|
|
2011-12-29 |
2011-12-27 |
S
Venta
|
KLASKIN CHRISTINE M
VP, Finance
Oficial
|
1 824
-12.6%
2,14
3.903 US$
|
1 824
-12.6%
|
2,14
|
3.903 US$
|
|
|
2011-12-29 |
2011-12-27 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
3 156
-10.7%
2,14
6.754 US$
|
3 156
-10.7%
|
2,14
|
6.754 US$
|
|
|
2011-12-29 |
2011-12-27 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
2 169
-17.7%
2,14
4.642 US$
|
2 169
-17.7%
|
2,14
|
4.642 US$
|
|
|
2011-12-23 |
2011-12-23 |
S
Venta
|
KLASKIN CHRISTINE M
VP Finance
Oficial
|
511
-3.4%
2,20
1.123 US$
|
511
-3.4%
|
2,20
|
1.123 US$
|
|
|
2011-12-23 |
2011-12-23 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
886
-2.9%
2,20
1.947 US$
|
886
-2.9%
|
2,20
|
1.947 US$
|
|
|
2011-12-23 |
2011-12-23 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
608
-4.7%
2,20
1.336 US$
|
608
-4.7%
|
2,20
|
1.336 US$
|
|
|
2011-12-23 |
2011-12-23 |
S
Venta
|
Sharp Shalini
CFO
Oficial
|
795
-1.7%
2,20
1.747 US$
|
795
-1.7%
|
2,20
|
1.747 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
KLASKIN CHRISTINE M
VP Finance
Oficial
|
993
-6.2%
2,19
2.175 US$
|
993
-6.2%
|
2,19
|
2.175 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
1 716
-5.4%
2,19
3.759 US$
|
1 716
-5.4%
|
2,19
|
3.759 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
1 177
-8.4%
2,19
2.578 US$
|
1 177
-8.4%
|
2,19
|
2.578 US$
|
|
|
2011-12-23 |
2011-12-22 |
S
Venta
|
Sharp Shalini
CFO
Oficial
|
1 548
-3.2%
2,19
3.391 US$
|
1 548
-3.2%
|
2,19
|
3.391 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
KLASKIN CHRISTINE M
VP Finance
Oficial
|
1 975
-11.0%
2,24
4.420 US$
|
1 975
-11.0%
|
2,24
|
4.420 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
Wentworth Kerry
VP, Clinical, Reg, & Quality
Oficial
|
3 414
-9.6%
2,24
7.641 US$
|
3 414
-9.6%
|
2,24
|
7.641 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
Valentine Karen
VP, General Counsel
Oficial
|
2 348
-14.3%
2,24
5.255 US$
|
2 348
-14.3%
|
2,24
|
5.255 US$
|
|
|
2011-12-23 |
2011-12-21 |
S
Venta
|
Sharp Shalini
CFO
Oficial
|
3 087
-6.0%
2,24
6.909 US$
|
3 087
-6.0%
|
2,24
|
6.909 US$
|
|
|
2011-10-03 |
2011-09-30 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
16 666
+1.9%
2,99
49.768 US$
|
16 666
+1.9%
|
2,99
|
49.768 US$
|
|
|
2011-08-17 |
2011-08-16 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
2 150 976
+67.7%
0,51
1.096.998 US$
|
2 150 976
+67.7%
|
0,51
|
1.096.998 US$
|
|
|
2010-05-19 |
2010-05-18 |
B
Compra
|
Wright Timothy
Consejero no ejecutivo
|
10 000
+inf%
1,34
13.400 US$
|
10 000
+inf%
|
1,34
|
13.400 US$
|
|
|
2010-03-18 |
2010-03-16 |
S
Venta
|
Valentine Karen
VP and General Counsel
Oficial
|
29 039
-36.1%
0,76
22.006 US$
|
29 039
-36.1%
|
0,76
|
22.006 US$
|
|
|
2009-06-29 |
2009-06-25 |
B
Compra
|
ARMEN GARO H
Chairman & CEO
Oficial
|
25 000
+2.2%
1,97
49.250 US$
|
25 000
+2.2%
|
1,97
|
49.250 US$
|
|
|
2009-02-25 |
2009-02-25 |
B
Compra
|
HATSOPOULOS JOHN
Consejero no ejecutivo
|
10 000
+22.2%
0,37
3.700 US$
|
10 000
+22.2%
|
0,37
|
3.700 US$
|
|
|
2008-09-05 |
2008-09-04 |
B
Compra
|
HATSOPOULOS JOHN
Consejero no ejecutivo
|
3 000
+7.1%
1,72
5.160 US$
|
3 000
+7.1%
|
1,72
|
5.160 US$
|
|
|
2008-09-05 |
2008-09-03 |
B
Compra
|
HATSOPOULOS JOHN
Consejero no ejecutivo
|
7 000
+20.0%
1,71
11.970 US$
|
7 000
+20.0%
|
1,71
|
11.970 US$
|
|
|
2008-05-20 |
2008-05-16 |
B
Compra
|
MARGARET EISEN
Consejero no ejecutivo
|
15 000
+300.0%
2,36
35.348 US$
|
15 000
+300.0%
|
2,36
|
35.348 US$
|
|
|
2008-01-11 |
2008-01-09 |
B
Compra
|
ARMEN GARO H
Chairman and CEO
Oficial
|
1 166 667
+10.2%
3,00
3.500.001 US$
|
1 166 667
+10.2%
|
3,00
|
3.500.001 US$
|
|